NASDAQ:CYCC - Cyclacel Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.46 +0.01 (+0.69 %)
(As of 07/15/2018 04:00 PM ET)
Previous Close$1.46
Today's Range$1.46 - $1.53
52-Week Range$1.28 - $3.74
Volume12,971 shs
Average Volume37,860 shs
Market Capitalization$17.52 million
P/E RatioN/A
Dividend YieldN/A
Beta3.69
Cyclacel Pharmaceuticals logoCyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. Its oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase (CDK) inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors. In addition, the company's oncology development programs include CYC140, a polo-like kinase inhibitor program that is in preclinical development stage. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

Receive CYCC News and Ratings via Email

Sign-up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CYCC
CUSIPN/A
Phone908-517-7330

Debt

Debt-to-Equity RatioN/A
Current Ratio5.82
Quick Ratio5.82

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$840,000.00
Price / Sales20.86
Cash FlowN/A
Price / CashN/A
Book Value$1.83 per share
Price / Book0.80

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-7,470,000.00
Net MarginsN/A
Return on Equity-37.72%
Return on Assets-30.76%

Miscellaneous

Employees12
Outstanding Shares12,000,000
Market Cap$17.52

The Truth About Cryptocurrencies

Cyclacel Pharmaceuticals (NASDAQ:CYCC) Frequently Asked Questions

What is Cyclacel Pharmaceuticals' stock symbol?

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work?

Cyclacel Pharmaceuticals shares reverse split on Tuesday, May 31st 2016. The 1-12 reverse split was announced on Friday, May 27th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 27th 2016. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 8 shares after the split.

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) posted its earnings results on Monday, May, 14th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.13) by $0.01. View Cyclacel Pharmaceuticals' Earnings History.

What is the consensus analysts' recommendation for Cyclacel Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Cyclacel Pharmaceuticals' key competitors?

Who are Cyclacel Pharmaceuticals' key executives?

Cyclacel Pharmaceuticals' management team includes the folowing people:
  • Mr. Spiro George Rombotis, CEO, Pres & Exec. Director (Age 59)
  • Mr. Paul McBarron, CFO, COO, Exec. VP of Fin., Sec. & Exec. Director (Age 57)
  • Dr. Judy H. Chiao M.D., VP of Clinical Devel. & Regulatory Affairs (Age 58)
  • Prof. David Glover Ph.D., FRS FRSE, Chief Scientist (Age 70)
  • Ms. Gill Christie, Director of HR (Age 61)

Has Cyclacel Pharmaceuticals been receiving favorable news coverage?

Press coverage about CYCC stock has been trending somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cyclacel Pharmaceuticals earned a news impact score of 0.09 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 45.51 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cyclacel Pharmaceuticals' stock price today?

One share of CYCC stock can currently be purchased for approximately $1.46.

How big of a company is Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals has a market capitalization of $17.52 million and generates $840,000.00 in revenue each year. Cyclacel Pharmaceuticals employs 12 workers across the globe.

How can I contact Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company can be reached via phone at 908-517-7330 or via email at [email protected]


MarketBeat Community Rating for Cyclacel Pharmaceuticals (NASDAQ CYCC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  80 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  168
MarketBeat's community ratings are surveys of what our community members think about Cyclacel Pharmaceuticals and other stocks. Vote "Outperform" if you believe CYCC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYCC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.